LONG-TERM COST EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS GLP-1 ADDED TO BASAL INSULIN AS INTENSIFICATION THERAPIES IN TYPE 2 DIABETES MELLITUS IN SPAIN
Author(s)
Prades M1, Lizan L2, Hunt B3, Ramirez de Arellano A4
1Outcomes'10, Castellon, Spain, 2Outcomes 10, Castellon, Spain, 3Ossian, Basel, Switzerland, 4Novo Nordisk Ltd, Madrid, Spain
OBJECTIVES: Compare the long-term clinical and costs outcomes associated with IDegLira versus GLP-1 added to basal insulin in type 2 diabetes (T2DM) patients uncontrolled on basal insulin from the perspective of the Spanish National Health System. METHODS: The analysis was based on the IMS CORE Diabetes Model. Treatment effects applied in year 1 were obtained from a published pooled analysis using data from treatment arms from five randomized clinical trials involving T2DM patients uncontrolled on basal insulin and with similar insulin titration goals. Utilities associated with diabetes and their complications were included in the model. Using a time horizon of 50 years, the model estimated life years (LY), quality-adjusted life years (QALY), cumulative incidence of diabetes-related complications, time to onset of diabetes-related complications and costs. The incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) were calculated. RESULTS: IDegLira was associated with increased discounted life years (14.34 versus 14.28 years) and discounted QALYs (9.25 versus 9.18 QALYs) compared to GLP-1 added to basal insulin. IDegLira was also associated with a higher reduction in incidence, and extended time to onset, of diabetes-related complications. Life time costs per patient were lower with IDegLira than GLP-1 added to basal insulin (€53,984 versus €55,713). ICER estimations and a comprehensive range of sensitivity analyses showed that IDegLira is a dominant treatment (i.e. more effective and less costly) compared to GLP-1 added to basal insulin. CONCLUSIONS: IDegLira is a less costly and more effective alternative for the treatment of patients with T2DM uncontrolled on basal insulin compared with GLP-1 added to basal insulin, from the perspective of the National Health System in Spain.
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PRM158
Topic
Methodological & Statistical Research
Topic Subcategory
Confounding, Selection Bias Correction, Causal Inference
Disease
Diabetes/Endocrine/Metabolic Disorders